



**Proteomics International**

LABORATORIES LTD

**ASX Release**  
**3 November 2023**

**ASX code: PIQ**

## **Update on presentation to the American Society of Nephrology Conference**

Proteomics International Laboratories Ltd (Proteomics International; the Company; ASX: PIQ) was invited to present its latest internal study on the economic health benefits of early detection and treatment in diabetes related kidney disease management (the Study) at the conference to be held by the American Society of Nephrology (ASN) "Kidney Week 2023" from 2-5 November 2023 in Philadelphia, USA. The preliminary study outcomes were published in the Journal of the American Society of Nephrology Abstract Supplement for the Kidney Week 2023 conference (Journal).<sup>1</sup>

Following consultation with ASX, Proteomics International retracts the prospective financial information and forward looking statements published in the Journal as the Company does not have a reasonable basis for the prospective financial information and forward looking statements. In retracting the publication in the Journal, Proteomics International advises that investors should not rely on the information as a basis for making an investment decision about its shares.

Authorised by Dr Richard Lipscombe (Managing Director) and Mr Neville Gardiner (Non-Executive Chairman) on behalf of the Board of PIQ.

ENDS

### **About Proteomics International Laboratories (PILL) ([www.proteomicsinternational.com](http://www.proteomicsinternational.com))**

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

### **For further information please contact:**

Dr Richard Lipscombe  
Managing Director  
Proteomics International Laboratories Ltd  
T: +61 8 9389 1992  
E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com)

Dirk van Dissel  
Investor Relations & Corporate Advisor  
Candour Advisory  
T: +61 408 326 367  
E: [dirk@candouradvisory.com.au](mailto:dirk@candouradvisory.com.au)

Kyle Moss  
Corporate Advisor  
Euroz Hartleys  
T: +61 8 9488 1400  
E: [kmoss@eurozhartleys.com](mailto:kmoss@eurozhartleys.com)

---

<sup>1</sup> Kidney Week 2023 Abstract Supplements (page 20): <https://www.asn-online.org/abstracts/>